Lazard Asset Management
ADMA icon

Lazard Asset Management’s ADMA Biologics ADMA Stock Holding History

Lazard Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116K Sell
13,823
-15,934
-54% -$145K ﹤0.01% 1735
2026
Q1 		$268K Sell
29,757
-20,880
-41% -$330K ﹤0.01% 1542
2025
Q4 		$924K Buy
50,637
+16,028
+46% +$270K ﹤0.01% 1180
2025
Q3 		$507K Buy
34,609
+513
+2% +$8.79K ﹤0.01% 1346
2025
Q2 		$619K Sell
34,096
-385,571
-92% -$7.86M ﹤0.01% 1442
2025
Q1 		$8.32M Buy
419,667
+71,068
+20% +$1.23M 0.01% 532
2024
Q4 		$5.98M Buy
348,599
+96,689
+38% +$1.82M 0.01% 591
2024
Q3 		$5.03M Buy
251,910
+48,802
+24% +$759K 0.01% 629
2024
Q2 		$2.27M Buy
203,108
+92,299
+83% +$774K ﹤0.01% 838
2024
Q1 		$730K Buy
110,809
+5,731
+5% +$31.3K ﹤0.01% 987
2023
Q4 		$474K Buy
105,078
+1,327
+1% +$4.91K ﹤0.01% 1126
2023
Q3 		$370K Buy
103,751
+18,295
+21% +$70.4K ﹤0.01% 1221
2023
Q2 		$314K Buy
85,456
+7,429
+10% +$27.5K ﹤0.01% 1227
2023
Q1 		$258K Hold
78,027
– – ﹤0.01% 1252
2022
Q4 		$302K Hold
78,027
– – ﹤0.01% 1215
2022
Q3 		$189K Hold
78,027
– – ﹤0.01% 1279
2022
Q2 		$154K Buy
78,027
+31,151
+66% +$61.3K ﹤0.01% 1355
2022
Q1 		$85K Buy
46,876
+7,309
+18% +$11.4K ﹤0.01% 1471
2021
Q4 		$55K Buy
+39,567
New +$52K ﹤0.01% 1692

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Lazard Asset Management's ADMA Position: Q2 2026 in Review

Lazard Asset Management reduced its ADMA Biologics (ADMA) stake by 54% in Q2 2026, selling an estimated $145K and leaving 13,823 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #1735.

Lazard Asset Management first reported a position in ADMA in Q4 2021 and has held it in 19 quarters since. The position peaked at $8.32M in Q1 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Lazard Asset Management held 13,823 shares of ADMA Biologics worth $116K as of Q2 2026.
  • Lazard Asset Management sold 15,934 ADMA Biologics shares in Q2 2026, an estimated $145K.
  • ADMA Biologics made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1735 holding.
  • Lazard Asset Management first reported a position in ADMA Biologics in Q4 2021 and has held it in 19 quarters since.
  • Lazard Asset Management's ADMA Biologics position peaked at $8.32M in Q1 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.